First Time Loading...
S

Shenzhen Weiguang Biological Products Co Ltd
SZSE:002880

Watchlist Manager
Shenzhen Weiguang Biological Products Co Ltd
SZSE:002880
Watchlist
Price: 30.03 CNY 5.52% Market Closed
Updated: May 2, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
Shenzhen Weiguang Biological Products Co Ltd

Wall Street analysts forecast Shenzhen Weiguang Biological Products Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Shenzhen Weiguang Biological Products Co Ltd is 42.84 CNY with a low forecast of 42.42 CNY and a high forecast of 44.1 CNY.

Lowest Forecast
Wall Street Target
42.42 CNY
41% Upside
Average Forecast
Wall Street Target
42.84 CNY
43% Upside
Highest Forecast
Wall Street Target
44.1 CNY
47% Upside
Lowest
Price Target
42.42 CNY
41% Upside
Average
Price Target
42.84 CNY
43% Upside
Highest
Price Target
44.1 CNY
47% Upside
Shenzhen Weiguang Biological Products Co Ltd Competitors:
Price Targets
MOR
MorphoSys AG
13% Downside
ZYME
Zymeworks Inc
70% Upside
E
1952
Everest Medicines Ltd
0% Downside
4597
Solasia Pharma KK
221% Upside
MOR
MorphoSys AG
13% Downside
ZYME
Zymeworks Inc
70% Upside
E
1952
Everest Medicines Ltd
0% Downside
4597
Solasia Pharma KK
221% Upside
KRRO
Korro Bio Inc
117% Upside
B
2315
Biocytogen Pharmaceuticals Beijing Co Ltd
167% Upside
688366
Shanghai Haohai Biological Technology Co Ltd
35% Upside
688266
Suzhou Zelgen Biopharmaceuticals Co Ltd
7% Upside

Revenue
Forecast

Revenue Estimate
Shenzhen Weiguang Biological Products Co Ltd

For the last 7 years the compound annual growth rate for Shenzhen Weiguang Biological Products Co Ltd's revenue is 4%. The projected CAGR for the next 3 years is 28%.

4%
Past Growth
28%
Estimated Growth
Estimates Accuracy
-21%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Shenzhen Weiguang Biological Products Co Ltd

For the last 7 years the compound annual growth rate for Shenzhen Weiguang Biological Products Co Ltd's operating income is -5%. The projected CAGR for the next 3 years is 50%.

-5%
Past Growth
50%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Shenzhen Weiguang Biological Products Co Ltd

For the last 7 years the compound annual growth rate for Shenzhen Weiguang Biological Products Co Ltd's net income is -1%. The projected CAGR for the next 3 years is 39%.

-1%
Past Growth
39%
Estimated Growth
Estimates Accuracy
-6%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Shenzhen Weiguang Biological Products Co Ltd's stock price target?
Price Target
42.84 CNY

According to Wall Street analysts, the average 1-year price target for Shenzhen Weiguang Biological Products Co Ltd is 42.84 CNY with a low forecast of 42.42 CNY and a high forecast of 44.1 CNY.

What is Shenzhen Weiguang Biological Products Co Ltd's Revenue forecast?
Projected CAGR
28%

For the last 7 years the compound annual growth rate for Shenzhen Weiguang Biological Products Co Ltd's revenue is 4%. The projected CAGR for the next 3 years is 28%.

What is Shenzhen Weiguang Biological Products Co Ltd's Operating Income forecast?
Projected CAGR
50%

For the last 7 years the compound annual growth rate for Shenzhen Weiguang Biological Products Co Ltd's operating income is -5%. The projected CAGR for the next 3 years is 50%.

What is Shenzhen Weiguang Biological Products Co Ltd's Net Income forecast?
Projected CAGR
39%

For the last 7 years the compound annual growth rate for Shenzhen Weiguang Biological Products Co Ltd's net income is -1%. The projected CAGR for the next 3 years is 39%.

ALPHA SPREAD
Join more than 133,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.